COMP <GO>
NUWE vs VBIO // FORWARD P/E MULTIPLE
Nuwellis Inc. (NASDAQ) VS. Valion Bio Inc. (NASDAQ) • 15-METRIC TALLY: NUWE 3
— VBIO 0
■ METRIC PARITY
LAST: $5.78 (+2.12%) • MKT CAP: $2.3M
forward-pe
—
LAST: $0.62 (-9.13%) • MKT CAP: $1.3M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUWE VS. VBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUWE | VBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | NUWE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 89.8 | 20.1 | +69.78 | NUWE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.3M | $1.3M | $1.0M | NUWE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUWE REV | VBIO REV | NUWE GROSS % | VBIO GROSS % | NUWE FCF | VBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $0 | 62.0% | — | -$10.9M | -$7.0M |
| FY 2024 | $8.7M | $780.0K | 64.9% | 0.3% | -$9.7M | -$5.7M |
| FY 2023 | $8.9M | $1.2M | — | — | -$17.9M | -$8.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUWE // BETA —
VBIO // BETA —